The estimated Net Worth of Bioventures Iii Qp Lpmpm Bi... is at least $8.38 Million dollars as of 2 June 2004. Bioventures Bi owns over 357,100 units of Cortexyme Inc stock worth over $8,381,939 and over the last 20 years Bioventures sold CRTX stock worth over $0.
Bioventures has made over 1 trades of the Cortexyme Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Bioventures bought 357,100 units of CRTX stock worth $2,499,700 on 2 June 2004.
The largest trade Bioventures's ever made was buying 357,100 units of Cortexyme Inc stock on 2 June 2004 worth over $2,499,700. On average, Bioventures trades about 357,100 units every 0 days since 2004. As of 2 June 2004 Bioventures still owns at least 4,298,430 units of Cortexyme Inc stock.
You can see the complete history of Bioventures Bi stock trades at the bottom of the page.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, and Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: